low Estradiol and high Total Testosterone associated with high risk of ischemic heart disease. This study looked at endogenous levels in women. This data as well as others really brings into question the massive prescription Testosterone push in women.
Study finds that "midrange" Testosterone and DHT associated with a reduced ischemic heart disease and death rate. No association was found with Estradiol. One flaw of this study is in their use of serum.
Older men, 70-89, Testosterone in the middle range of normal and higher DHT was associated with the lowest death rates. Estradiol was not found to be associated. This study only looked at Total levels, free bioavailable levels were not assessed. This study also highlights the basic thought, that more is not always better as it pertains to Testosterone. It also highlights the importance of DHT. Testosterone is a pro hormone.
T3 in the post MI individual decreases the MI infarct size and the progression to heart failure. What is really interesting about this study is that the T3 induced mitochondrial biogenesis and activity which is a great thing in recovery of MI and also in disease i.e. cancer. However, it appears to increase HIF-1alpha and angiogenesis which is stimulated by retrograde signaling. There is a muddied picture here. Because T3 stimulates oxidative phosphorylation and mitochondria biogenesis which is favorable for health. However, in this study of rats, it induced HIF-1alpha and angiogenesis in post MI, which is favorable to recovery, yet this is unfavorable for cancer. Yet oxidative phosphorylation is favorable to cancer prevention/elimination and MI recovery.
Australian study of older men, 70-89, found that normal Testosterone and DHT levels were associated with lower death rates. This is important as this is the first study to find the positive health benefit of DHT as well as Testosterone.
Testosterone shown to have vasodilatory effect in men. In this small study, the short course of IV testosterone reduced exercise induced heart ischemia. This was in men with pre-existing CAD.